Skip to main content
Home
  • fr
  • en
  • Profile
    • Leadership team
    • Supervisory board
    • Scientific advisory board
    • Founders
    • History
    • Key figures
    • Key competencies
  • Science
    • Innate Pharma, the innate immunity company
    • Immunity & Immunotherapy
    • Bibliography
  • Pipeline
    • IPH4102
    • Monalizumab
    • IPH5401
    • Lirilumab
    • IPH52
    • IPH53
    • IPH4301
    • Anti-Siglec-9

    • Monoclonal antibodies
    • ADC technology
    • Bispecific antibodies
  • Partnering
  • Investors
    • Regulated information & publications
    • Share information
    • Investor Kit
    • Corporate governance
    • Financial Calendar
    • Investor relations
  • News & events
    • Press releases
    • Events
    • Innate in the news
  • Career
  1. Home
  2. Investors
  3. Regulated information & publications
  4. All press releases

All press releases

  • Preliminary data suggest promising anti-tumor activity of the combination of monalizumab and cetuximab in patients with platinum pretreated SCCHN

    April 17, 2018
    8 partial responses (PR) among 26 patients evaluable for efficacy – predefined number of responses needed to declare the trial result positive has been reached The combination was well tolerated,...
  • New preclinical data further support ongoing programs and highlight next generation of immunotherapies

    April 17, 2018
    Next generation of immunotherapies presented by Chief Scientific Officer Eric Vivier in a meet-the-expert session at AACR 2018 New preclinical data further support ongoing clinical trials with...
  • Upcoming investor conferences

    April 9, 2018
    Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor events: H.C. Wainwright Global Life Sciences Conference –...
  • Partner MedImmune expands colorectal cancer patient cohort in ongoing Phase I trial evaluating monalizumab in combination with Imfinzi® (durvalumab)

    March 23, 2018
    Additional expansion cohorts to explore the safety and efficacy of monalizumab in combination with durvalumab and standard of care in patients with 1 st - and 2 nd line, metastatic colorectal cancer...
  • Innate Pharma to present broad and innovative portfolio in immuno-oncology at AACR 2018

    March 15, 2018
    First clinical activity data of the combination of monalizumab and cetuximab New preclinical data further supporting the rationale of Innate’s first- or best-in-class antibodies Eric Vivier, Chief...
  • Innate Pharma Hosts R&D Day Today in London

    March 8, 2018
    Innate Pharma presents a clinical update on its broad and diverse development portfolio of first- or best-in-class antibodies in immuno-oncology Update on the development program with AstraZeneca on...
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  •  ›
  •  »
Updated on Tue, 12/06/2016 - 20:57

Investors

  • Regulated information & publications
    • All press releases
    • Financial reports
    • Corporate Social Responsibility
    • General Shareholders' Meeting documents
    • Number of shares and voting rights
    • Articles of association
    • Code of Ethics
    • Share repurchase: liquidity agreement
    • Declaration by the Management Board and the Supervisory Board members
    • Prospectus related to public offerings
    • Appraiser reports
  • Share information
  • Investor Kit
  • Corporate governance
  • Financial Calendar
  • Investor relations
  • Contact
  • Location
  • Site map
  • Legal Info

Profile

  • Leadership team
  • Supervisory board
  • Scientific advisory board
  • Founders
  • History
  • Key figures
  • Key competencies

Science

  • Innate Pharma, the innate immunity company
  • Immunity & Immunotherapy
  • Bibliography

Pipeline

  • IPH4102
  • Monalizumab
  • IPH5401
  • Lirilumab
  • IPH52
  • IPH53
  • IPH4301
  • Anti-Siglec-9

  • Monoclonal antibodies
  • ADC technology
  • Bispecific antibodies

Partnering

Investors

  • Regulated information & publications
    • All press releases
    • Financial reports
    • Corporate Social Responsibility
    • General Shareholders' Meeting documents
    • Number of shares and voting rights
    • Articles of association
    • Code of Ethics
    • Share repurchase: liquidity agreement
    • Declaration by the Management Board and the Supervisory Board members
    • Prospectus related to public offerings
    • Appraiser reports
  • Share information
  • Investor Kit
  • Corporate governance
  • Financial Calendar
  • Investor relations

News & events

  • Press releases
  • Events
  • Innate in the news

Career

Follow us

Stay in touch

Subscribe to our newsletter

Contact us

117, Avenue de Luminy - BP 30191
13 009 Marseille FRANCE

+33 (0)4 30 30 30 30

Home